Ibogaine is drawing new interest from the Trump administration. Here’s what to know about the psychedelic
The Trump administration has launched a new effort to accelerate research into ibogaine, a powerful psychedelic compound derived from the African iboga plant. President Donald Trump signed an executive order aimed at reducing regulatory barriers and expanding clinical studies on psychedelic therapies for serious mental illnesses and addiction. (The White House) Key points:
